Treatment of Non-Culprit Lesions in STEMI: An Incomplete Journey

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Research

Background:

• Multivessel coronary artery disease (CAD) affects approximately 50% of ST-segment elevation myocardial infarction (STEMI) patients.
• Complete revascularization (CR) has demonstrated safety and efficacy in reducing adverse cardiac events, particularly myocardial infarction (MI) and repeat revascularization.

Purpose of the Study:

• To review the evidence base for CR in STEMI patients with multivessel CAD.
• To highlight the limitations of current randomized trials regarding CR.
• To emphasize the need for mechanistic insights into the benefits of revascularizing non-infarct related arteries (NIRA).

Main Methods:

• Systematic review of existing randomized studies on complete revascularization in STEMI.
• Analysis of reported clinical outcomes, including repeat revascularization and MI.
• Discussion of the variability in trial results and the lack of mechanistic understanding.

Main Results:

• CR, whether immediate or delayed, is safe and reduces the risk of repeat coronary revascularization and MI.
• Existing trials show variable results, suggesting different underlying mechanisms for CR's benefit.
• No study has yet provided a mechanistic explanation for the benefits of revascularizing chronic bystander lesions in NIRA.

Conclusions:

• Understanding the mechanisms of CR benefit in NIRA is crucial for identifying patient subgroups most likely to benefit.
• The current "one size fits all" approach to CR may not be optimal.
• Further research is needed to elucidate the specific pathways through which revascularizing NIRA confers clinical advantage.